The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

Research output: Contribution to journalReview articlepeer-review

234 Scopus citations

Abstract

The identification of tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, both clinical and animal studies suggest that therapeutic strategies that have mainly focused on the use of CD8+ T cells (and MHC class I-restricted tumor antigens) are not effective in eliminating cancer cells. Recent interest has been directed towards the use of CD4+ T cells in generating antitumor immunity. To this end, the identification of MHC class II-restricted tumor antigens that can stimulate CD4+ T cells might provide opportunities for developing effective cancer vaccines.

Original languageEnglish (US)
Pages (from-to)269-276
Number of pages8
JournalTrends in Immunology
Volume22
Issue number5
DOIs
StatePublished - Aug 1 2001

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'The role of MHC class II-restricted tumor antigens and CD4<sup>+</sup> T cells in antitumor immunity'. Together they form a unique fingerprint.

Cite this